Home / Business and Economy / Arcutis: ZORYVE Growth Fuels Biotech's Self-Sustaining Future
Arcutis: ZORYVE Growth Fuels Biotech's Self-Sustaining Future
10 Jun
Summary
- ZORYVE shows strong growth, with projected peak sales of $2.5B-$3B.
- Arcutis is now cash-flow positive, enabling R&D investment.
- Upcoming FDA decision for younger psoriasis patients is expected June 29.
Arcutis Biotherapeutics is highlighting the significant growth trajectory of its drug ZORYVE, with executives anticipating peak sales ranging from $2.5 billion to $3 billion. The company has successfully transitioned to a cash-flow positive state, a notable achievement in the biotech sector. This financial stability enables Arcutis to continue supporting ZORYVE's current indications while reinvesting in its research and development pipeline.
The company anticipates several key regulatory and clinical developments in the coming year. A primary catalyst is the potential FDA approval for ZORYVE in psoriasis patients aged 2 to 5, with a decision due by June 29, 2026. Arcutis has also submitted for approval for atopic dermatitis in infants, expecting a decision early in 2027. Furthermore, clinical studies for ZORYVE in vitiligo and hidradenitis suppurativa are progressing, with study results expected by the end of 2026 and early 2027, respectively.
